Bavarian Nordic gains important US order for 20 million vaccine doses  

2007.04.17
Bavarian Nordic has received notification from the US Department of Health and Human Services that it intends to procure 20 million doses of smallpox vaccine
Danish biotech company Bavarian Nordic has received notification from the US Department of Health and Human Services (HHS) that it intends to procure 20 million doses of the company's third generation Imvamune smallpox vaccine for the strategic national stockpile. Bavarian Nordic has been waiting for some time to gain the order, which previously has been estimated to be worth DKK 3 bn (USD 540 m). The company's chairman, Asger Aamund, is naturally delighted at the news:
 
"Bavarian Nordic will now develop from being a large Danish biotech company into becoming a pharmaceutical concern with its own production and a large sales apparatus."
 
While the principal terms of the agreement have been reached, the contract is still being finalised. It is expected to be the first HHS procurement contract under the BioShield programme since the enactment of the Pandemic and All-Hazards Preparedness Act came into force in December 2006.
 
When the news broke Monday morning, Bavarian Nordic's share price shot up 12.7% to DKK 600 (USD 108), its highest ever level in the nine years Bavarian Nordic has been in existence.
 
Bavarian Nordic has operations in Denmark, Germany, the US and Singapore. The company's patented MVA-BN technology is one of the world's safest multivalent vaccine vectors for development of vaccines against infectious diseases (smallpox and HIV) and cancer. Bavarian Nordic has ongoing development contracts with the US government to develop Imvamune as a safe third-generation smallpox vaccine. The news was reported by financial daily newspaper Børsen and on Bavarian Nordic's website.
 
Link > Bavarian Nordic  

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×